By Fineline Cube 
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its allisartan-indapamide combination drug, marking China’s first ARB (Angiotensin Receptor Blocker) plus thiazide-like diuretic compound antihypertensive medication.
Drug Details
This domestically developed original compound sustained-release formulation is designed for the treatment of primary hypertension. The combination of allisartan isoproxil and indapamide helps mitigate adverse reactions such as hypokalemia and increased uric acid levels often caused by diuretics. It is particularly suitable for patients with salt-sensitive hypertension, elderly and very elderly hypertensive patients, isolated systolic hypertension, hypertension complicated with diabetes, obesity or metabolic syndrome, and chronic heart failure.
Clinical Results
Clinical trial results showed that by the 12th week of the double-blind treatment period, the mean sitting systolic blood pressure (msSBP) of the compound formulation group decreased by 15.22 mmHg from baseline. Further reductions were observed at 20, 28, and 40 weeks, indicating that long-term treatment with this compound can further optimize blood pressure control.-Fineline Info & Tech